BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 12629411)

  • 1. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
    Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
    J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
    Ribeiro-Filho LA; Franks J; Sasaki M; Shiina H; Li LC; Nojima D; Arap S; Carroll P; Enokida H; Nakagawa M; Yonezawa S; Dahiya R
    Mol Carcinog; 2002 Aug; 34(4):187-98. PubMed ID: 12203370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions.
    Chiles MC; Ai L; Zuo C; Fan CY; Smoller BR
    Mod Pathol; 2003 Oct; 16(10):1014-8. PubMed ID: 14559984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma.
    Kao RH; Huang LC; Hsu YH
    Anticancer Res; 2002; 22(6C):4109-13. PubMed ID: 12553040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methyltransferase 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma.
    Shieh YS; Shiah SG; Jeng HH; Lee HS; Wu CW; Chang LC
    Cancer; 2005 Sep; 104(5):1013-21. PubMed ID: 15999364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
    Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
    Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
    Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
    J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
    Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
    J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas.
    Matsumura T; Makino R; Mitamura K
    Clin Cancer Res; 2001 Mar; 7(3):594-9. PubMed ID: 11297254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
    Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
    Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
    Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
    J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
    Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
    Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
    Chang HW; Chow V; Lam KY; Wei WI; Yuen A
    Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma.
    Paterson RF; Ulbright TM; MacLennan GT; Zhang S; Pan CX; Sweeney CJ; Moore CR; Foster RS; Koch MO; Eble JN; Cheng L
    Cancer; 2003 Nov; 98(9):1830-6. PubMed ID: 14584063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
    Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
    BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.